Table 1.
Patient and treatment characteristics.
| Characteristic | n = 70 |
|---|---|
| Age (years) | 61 (29–83) |
| Sex male/female | 34 (49%)/36 (51%) |
| Smoking historya | 16 (23%) |
| Histology | |
| Thymoma | 41 (59%) |
| A/AB/B1/B2/B3b | 4/1/4/18/11/3 |
| Thymic carcinoma | 29 (41%) |
| SCC/LCNEC/adenocarcinoma | 26/2/1 |
| Stage | |
| T1/2/3/4 | 2 (3%)/8 (11%)/28 (40%)/23 (33%) |
| Local recurrence | 9 (13%) |
| N0/1/2 | 55 (78%)/6 (9%)/9 (13%) |
| M0/1a/1b | 49 (21%)/14 (10%)/7 (10%) |
| Surgery | 46 (66%) |
| Chemotherapy use | 34 (49%) |
| Steroid therapy use | 21 (30%) |
| RT technique | |
| 3DCRT/IMRT | 66 (94%)/4 (6%) |
| RT dose (Gy) | |
| Median total dose | 58.3 (15.0–70.0) |
| Median fraction dose | 2.0 (1.5–2.5) |
| Median EQD2 dose | 56.9 (13.5–70.0) |
| Overall treatment time (days) | 43 (13–112) |
| GTV volume (cc) | 69.5 (2.0–1564) |
| Lung volume (cc) | 2,228 (1,110–5,246) |
| Lung V20 (%) | 16.6 (0–48.9) |
| Mean lung dose (Gy) | 9.7 (2.0–24.7) |
| Mean heart dose (Gy) | 14.9 (0.4–44.9) |
| Mean left atrium dose (Gy) | 17.8 (0.3–49.1) |
| Mean left ventricle dose (Gy) | 2.1 (0.1–39.7) |
| Mean right atrium dose (Gy) | 6.1 (0.1–56.5) |
| Mean right ventricle dose (Gy) | 4.6 (0.2–41.7) |
| Mean ascending aorta dose (Gy) | 37.9 (0.6–67.3) |
| Mean pulmonary artery dose (Gy) | 40.8 (0.9–60.4) |
Data are shown as n (%) or medians (range). Data were described as equivalent 2-Gy fractions (EQD2) using the LQ model with α/β = 3 Gy outside the median total dose. The tumor bed was regarded as GTV for postoperative cases.
SCC squamous cell carcinoma, LCNEC large cell neuroendocrine carcinoma, RT radiotherapy, 3DCRT three-dimensional conformal RT, IMRT intensity-modulated radiation therapy, EQD2 equivalent 2-Gy fractions, GTV gross tumor volume, V20 percentage volume receiving at least 20 Gy.
aMissing in 9 patients. bWorld Health Organization (WHO) classification, missing in 3 patients.